Gene therapy is a technique that allows doctors to treat a disorder by inserting genes into patients’ cells to mitigate the underlying genetic drivers of disease. Human cells can be re-engineered to create highly-effective hunter/killers of invasive pathogens or cancer cells, or reprogramed to produce secretions that provide potent remedies to other disease conditions. There is strong evidence that this new therapeutic technology may unlock treatments and cures for formally untreatable or incurable human diseases, such as inherited genetic disorders, infectious diseases, and cancer.
Pipeline
Our Executive Team
American Gene Technologies™ (AGT) is building a rich product pipeline based on its lentiviral vector platform. Our three leading therapeutics are well into the laboratory phase and scheduled to move into the clinical phase over the course of the next 6-18 months. AGT is in the process of testing and commercializing genetic medicines that will cure or halt the progression of several major diseases.
Jeffrey A. Galvin
CEO and
Founder
Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies.
C. David Pauza, PhD
Chief Science
Officer
David has 35 years of experience in HIV, immunology, virology, and cancer biology, and has held faculty positions and at University of Wisconsin and University of Maryland medical schools. Prior to joining AGT, David was Adjunct Professor of Medicine at the University of Maryland Medical School in Baltimore.
C. Neil Lyons, CPA
Chief Financial Officer &
Executive Vice President
Neil has more than 30 years of experience in finance, strategy, raising capital, SEC compliance, and corporate governance in both public and private companies, with over 10 years of that leading finance for publicly-traded, clinical-stage biotechnology companies.
Irene Tennant
Director,
Clinical Development
Irene brings more than 20 years of experience in clinical research and operations, and has led teams in support of the development of biopharma products and pharmaceutical first in class treatments in gene medicine, oncology, and infectious diseases.
Kelly Huang, PhD
Director, Preclinical
Product Development
Kelly brings more than 10 years of experience in biopharma drug development, and has lead teams to support the development of drugs targeting diverse therapeutic areas including infectious disease, autoimmunity, and oncology.
